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Infants below 28 weeks' gestation have low thyroid hormone plasma levels compared with more mature infants and this may contribute to their risk of developmental disability. We aimed to determine the effect of supplementation with levothyroxine (LT4) for extremely premature infants born below 28 weeks’ gestations on neurodevelopmental outcomes at 42 months.
METHODS
An explanatory double-blind randomized placebo-controlled trial consecutively recruited 153 infants below 28 weeks' gestation from five neonatal units in the United Kingdom. Infants were either supplemented with LT4 started intravenously during the first five days after birth and then changed to oral LT4 when enteral feeds were fully established (8 μg/kg birthweight/day as a single daily dose) or given placebo until 32 weeks' corrected gestational age (CGA). Neurodevelopmental outcomes at 42 months (range 40-43) was evaluated in 59 of these infants (30 LT4-supplemented, 29 placebo) using Bayley III Mental and Psychomotor Developmental Indices. Cognition outcomes was correlated with plasma free thyroxine level at 36 weeks and Diffusion Tensor Imaging (DTI) markers.

RESULTS
The LT-4 supplemented group performed significantly better in motor, language and cognitive function domains. The mean of the difference between each group (95% confidence intervals, p-value) was motor domain 6.96 (0.55-13.38, p=0.034); language domain 8.93 (0.16-17.70, p=0.041); cognition domain 6.35 (0.14-12.55, p=0.045). Neurodevelopmental outcome at 42 months had some associations with the trial’s primary outcome (subarachnoid space width and motor outcome, p=0.03), plasma free thyroxine level at 36 weeks (FT4 and cognition outcome, p=0.01), and Diffusion Tensor Imaging (DTI) at 36 weeks with cognition outcomes (p>0.05).
CONCLUSION






Among infants born at term, the disability associated with hypothyroidism in the immediate postnatal period can be prevented by giving supplementary thyroid hormone: even mild thyroid hormone insufficiency can produce measurable, but preventable deficits in neuropsychological functions (1). Infants born extremely prematurely have a high incidence of motor and cognitive deficits that are worse at lower gestations  ADDIN EN.CITE (2). Infants born at extreme prematurity (before 28 weeks gestation) are at high risk of developmental disability  ADDIN EN.CITE (3, 4), and up to 69% of infants born below 30 weeks’ gestation have low free thyroxine (FT4) concentrations compared to term infants  ADDIN EN.CITE (4-8). It is unclear whether the condition known as transient hypothyroxinaemia of prematurity (9) contributes to the causation of neurodisability and should be treated or if it is a marker of illness severity or a normal concomitant of prematurity. 
Some steps have been taken to address this problem. A Phase 1 trial of differing doses and modes of administration of thyroid hormones to 168 preterm neonates less than 28 weeks’ gestation found no difference in neurodevelopmental outcomes in relation to thyroid hormone treatment at 36 months of age  ADDIN EN.CITE (10). A previous large trial of LT4 supplementation recruited 200 infants <30 weeks’ gestation found no differences in outcomes for the whole sample, but a subgroup of 46 infants born <28 weeks’ gestation showed an improved Bayley Mental Development Index (MDI) and Psychomotor Development Index (PDI) at 2 years of age  ADDIN EN.CITE (7, 11). In the same study, survivors of the trial were assessed at the age of 5.7 years and an improved IQ score (effect size 0.65 of SD) was found in favor of the  most immature infants < 27 weeks’ gestation from LT4-supplemented group (12).  Another study found that early replacement therapy with LT4 in doses of 5-10 µg/kg/day initiated in the second week of life was associated with improved long-term mental development at 7 years of age in premature infants born with low birth weight <2500 grams (13). 
	Details and early results of the TIPIT trial have been reported previously  ADDIN EN.CITE (14, 15). In brief, TIPIT explored the effect of early supplementation with LT4 (8 μg/kg birthweight/day as a single daily dose) started intravenously during the first five days after birth and then changed to an oral preparation when enteral feeds were fully established and given until 32 weeks' corrected gestational age (CGA). There were no differences at 36 weeks’ CGA between infants given LT4 (n=78) or placebo (n=75) for width of the subarachnoid space, head circumference, body weight or mortality.  Although infants who received LT4 supplementation had significantly shorter leg lengths at 36 weeks’ CGA (p=0.02), there was no statistical difference when the analysis was adjusted for baseline length  ADDIN EN.CITE (14). TIPIT aimed to investigate whether early T4 supplementation improves brain growth measured at term-equivalence, using brain size as a surrogate outcome measure for neurological development. Multiple factors are likely to be implicated in normal brain development and the TIPIT study focussed on the status of thyroid axis at a time that neuronal migration has just been completed and synaptogenesis is taking place. Thyroid hormones are known to improve brain connectivity therefore improving central nervous connectivity at this vulnerable stage of development might reasonably be expected to improve higher functioning. Diffusion tensor imaging (DTI) makes it possible to observe white matter pathways before myelination is evident on conventional MRI and it enables measurements of apparent diffusion coefficient (ADC) and fractional anisotropy (FA) which are sensitive to the integrity and organisation of the white matter microstructure (16).





TIPIT was a multi-center randomized double blind placebo-controlled explanatory trial of postnatal LT4 supplementation given until 32 weeks’ corrected gestational age (CGA) to infants born below 28 weeks’ gestation. Multiple births were included with both infants randomized to the same arm. The following were excluded: infants born to mothers with known thyroid disease or on anti-thyroid medications or amiodarone,  infants with major congenital or chromosomal abnormalities known to affect thyroid function or brain development and maternal death. All infants previously recruited to the TIPIT study  ADDIN EN.CITE (14, 17) were eligible to take part in this follow-up study. A nested MRI study was done on 45 infants in the TIPIT study and previously reported  ADDIN EN.CITE (15).
A sample size of 30 in each group will have 80% power to detect a difference in means of 15.0 (Bayley’s MDI) assuming that the common standard deviation is 26.0 using a two group t-test with a 0.05 two-sided significance level. The value for the SD was taken from a previous study (11) which reported an 18 point difference in MDI between the thyroxine and placebo groups at 2 years. 

Recruitment
Parents were aware of the possibility of a follow-up study when they were recruited to the initial TIPIT from five tertiary level neonatal units  ADDIN EN.CITE (14). Mother and child were traced through the Office of National Statistics (ONS) and investigators were informed of the mother’s or child's death since discharge from hospital. An investigator made an initial approach by letter when the child was approaching 3 years of age to outline the study, discuss with parents the information sheet given and answer any immediate questions. The parents were given a period of reflection up to a month. Following this, parents were asked for consent to the inclusion of their child in the project. Following recruitment, a date and time were set to assess the child's developmental milestones either in a clinic setting or in the home environment. One blinded assessor evaluated neurodevelopmental outcome at 42 months in these infants using Bayley’s III Mental and Psychomotor Developmental Indices. The Bayley’s III Mental and Psychomotor Developmental Indices are used to assess the developmental status of children between 1 month to 42 months of age. This assessment takes 30 to 90 min to administer. Parents and caregivers were blinded to the allocation in the TIPIT trial. Cognitive scales on Bayley-III assess abilities such as sensorimotor development, exploration, concept, memory, and simple problem solving while the motor scale consists of fine motor and gross motor subtests. The cognitive outcome is reported as the composite cognitive score, which has a mean of 100 and a standard deviation of 15. Scaled scores are used for the Fine and Gross Motor scores separately, which have a mean of 10 and range from 1 to 19; this method of assessment has been validated and shown to provide reliability at this age in the prediction of final neurodevelopment  ADDIN EN.CITE (18, 19).

Analyses
Outcomes were measured as continuous variables. The difference between the two intervention groups was compared using a two-group t-test and the difference in means presented with a 95% confidence interval. Assumptions of normality were checked using a visual inspection of a histogram. Correlations were analyzed using Spearman’s correlation. The relationship between plasma FT4 concentrations and outcomes was explored using an approach described by van Wassenaer et al. (20). Thus the mean value of FT4 measurements at baseline, day 14, day 21 and day 28 were calculated and the effect of very low plasma FT4 concentrations was determined by measurements taken from babies in the placebo group; measurements from infants who had plasma FT4 concentrations in the lowest quartile were compared with those who had plasma FT4 concentrations in the upper three quartiles using a two-group t-test. The reasons were to explore the possible effects of the very low plasma FT4 concentrations on outcomes. A p-value of 0.05 or less was used to declare statistical significance for all analyses without adjustment for multiple comparisons.
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267 participants in TIPIT from five participating centers were assessed for eligibility and 153 infants were recruited to this follow-up study  ADDIN EN.CITE (14). Among infants recruited to the follow-up study, 78 infants received LT4 supplementation and 75 received placebo. There were no differences in baseline characteristics between eligible infants recruited to the follow-up study compared with infants not recruited to the follow-up study. The CONSORT flow diagram (Figure 1) shows the passage of all recruited and eligible participants. There were 16 deaths (10.4%) between discharge from hospital and the approach to families about follow-up, and 42 patients were unable to be contacted despite our best efforts. One patient had to be excluded due to a mis-labelled assessment. There was a large loss to follow-up despite every effort made to contact the families via their NHS numbers and GP practices. However, there were no significant differences in demographics between the two groups on analysis.
Baseline demographic characteristics between LT4-supplemented and placebo groups in the follow-up study are shown in Table 1 and there were no significant differences between the treatment and placebo groups. There were no differences in baseline characteristics or demographics between eligible infants recruited between the 5 participating centres and no differences between groups in number of complications




This extension to the TIPIT trial was designed to explore the effects and mechanisms of thyroxine supplementation on neurodevelopmental outcomes. Extremely preterm infants in the supplemented group performed significantly better in all three domains of the Bayley's III Mental and Psychomotor Developmental Indices at 42 months. Overall, the Bayley’s mean and median scores were noted to be lower compared to other preterm infant studies but direct comparisons are difficult to make as our population was more premature compared to some studies which included less premature infants  ADDIN EN.CITE (21), while other studies neurodevelopmental assessment were undertaken at a younger age  ADDIN EN.CITE (22).
Surrogate outcomes are important elements in the evaluation of interventions. Given the complexity of long-term outcome studies, TIPIT was designed using a single surrogate outcome: depth of subarachnoid space. This was selected because it had been validated and was associated with differences between groups defined by gestational age (23). The results of this study lend partial support to this choice: subarachnoid space width measured at 36 weeks was associated with motor outcomes at 42 weeks. Low ADC and high FA values were associated with more extensive myelination. Other studies have reported on the potential of DTI to identify antecedents of disordered brain microstructure among neonates born at extreme prematurity  ADDIN EN.CITE (24). Rose et al. found that abnormal neurodevelopment at 18 months corrected age was associated with lower FA values in the right posterior limb of the internal capsule  ADDIN EN.CITE (25). Van Kooij et al. have also reported that higher FA in the corpus callosum was associated with better cognitive performance at 2 years corrected age (26). Our study shows that FA at term correlated significantly with motor and cognitive composite scores at 42 months of age. This is a unique study reporting associations between thyroid hormone status, long term neurodevelopmental outcomes and DTI MRI variables in infants born at extreme prematurity.  These data support the use of subarachnoid space and DTI measures in future studies. 
The assessment of exposure to thyroxine supplementation and outcomes showed a relationship between higher plasma FT4 concentrations during the weeks after birth and better neurodevelopmental outcomes at 42 months. These differences however, only reached statistical significance for cognition composite scores and not for motor and language composite scores in the Bayley's III Mental and Psychomotor Developmental Indices. The assessment of exposure was relatively crude but is consistent with our other data. Of note, an MRI nested study of TIPIT found that infants with higher FT4 levels had lower ADC measurements at term-equivalence suggesting greater organization of the white matter consistent with increased myelination  ADDIN EN.CITE (15). The relationship between early plasma FT4 concentrations and outcomes on brain MRI measurements at term-equivalence and at development 42 months suggests that a future study should target infants with low plasma concentrations of FT4. 
Our findings are consistent with several observational studies that have documented associations between low thyroid hormone levels in the first weeks of life and abnormal neurodevelopmental outcomes  ADDIN EN.CITE (27-29). Reuss et al. reported a 4.4 fold increase in risk of disabling cerebral palsy at 2 years of age associated with low thyroid hormone levels in the early weeks of life of preterm infants born before 29 weeks’ gestation (30). Another study reported that early replacement therapy in 58 low-birth weight newborns can be beneficial for quicker motor development and better mental development in the 7th year of life (13). A Cochrane review of observational studies did not support the use of prophylactic thyroid hormones in preterm infants to reduce neonatal mortality, neonatal morbidity or improve neurodevelopmental outcomes and concluded that an adequately powered clinical trial of thyroid hormone supplementation in very preterm infants was required (31). However, early thyroxine treatment of children with Down’s syndrome did not seem to benefit mental or motor development later in life in another RCT. However, the positive effect on growth was measurable especially in infants with an elevated plasma TSH concentration in the neonatal period  ADDIN EN.CITE (32). It remains unclear if early thyroxine exposure has simply altered the tempo of development and not the ultimate outcome.
A limitation of this study is large number of infants lost to follow-up at 42 months which did not reach the sample size calculation despite every effort being made to contact the families. No significant differences in demographics were noted between the two groups. The original recruitment process was also consecutive, therefore all mothers/parents were asked for consent to recruitment. Due to the nature of the study, 43% were excluded if infants were not consented or fulfilled the exclusion criteria of the study protocol. 
This study is a randomized clinical trial specifically targeting extremely premature infants with thyroxine supplementation, and the third largest randomized trial of thyroid hormone supplemented infants born below 28 weeks’ gestation. MRI DTI measurements in infants with higher FT4 plasma concentrations during early life had lower ADC measurements at term-equivalence, suggesting greater organization of the white matter. Future larger scale trials would seem to be justified on the basis of the results reported here; these could usefully target preterm infants on the basis of their initial thyroid hormone levels. This study suggests that early supplementation with LT4 may improve long-term neurodevelopment in infants born below 28 weeks’ gestation but larger trials are needed and the modest improvements shown are not strong enough to warrant a change in practice.  
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Table 1: Demographics and baseline characteristics

	LT4 -supplemented  (n=30)	Placebo(n=29) 
Infants less than 28 weeks gestation randomised 	75	78
Sex (males)	44 (59%)	45 (58%)
Birth weight (grams)	820.7 (183.9)	842.2 (200.0)
Gestational age (weeks)	25.8 (1.3)	25.8 (1.4)
Clinical Risk Index for Babies (CRIB) score 	5.7 (3.5)	5.4 (4.1)
No of twin births (pairs)	4 (5.3%)	6 (7.7%)
Infant baseline FT4 (pmol/L)	12.2 (6.9)	10.5 (6.3)
Infant baseline leg length (mm)	38.7 (7.1)	39.54 (6.8)
Maternal age (years)	28.8 (5.8)	28.9 (5.8)
Died	7	9
Unable to contact 	24	18
Mis-labelled Assessment	0	1
Cohort assessed by Bayley’s III Mental and Psychomotor Developmental Indices at 42 months 	30	29
Cohort assessed by subarachnoid space width at 36 weeks	61	57

CRIB, Clinical risk index for babies 












Table 2a. Bayley’s III Composite Scores at 42 months of age of all infants
N=59 	Mean ± SD	Median (Range)
Age (m)	42 ± 1.0	42 (40-43)
Cognitive	88 ± 12.2	90 (85-110)
Language	88 ± 17.3	94 (47-112)







Table 2b. Bayley’s III composite ccores at 42 months of age between treated group and placebo group
	LT4 -supplemented(n=30)	Placebo (n=29)	Mean diff (95% CI) 	P-value
Age (mean ± SD)	42.1 ± 0.8	41.7 ± 1.3	0.4 (-1.8, 2.1)	0.482
Head circumference (cm)	51.5 ±8.7	50.2 ±2.3	1.35 (-2.2, 4.9)	0.443
Height (cm)	96.2 ±8.3	98.0 ±7.5	-1.8 (-6.2, 2.7)	0.426
Weight (kg)	14.0 ±4.0	15.7 ±3.1	-1.7 (-3.8, 0.4)	0.110
Motor	84 ±12	77 ±13	6.96 (0.55-13.38)	0.034
Language	92 ±13	83 ±20	8.93 (0.16-17.70)	0.041



























Internal Capsule-Right	Mean Fibre Length	0.37	0.043	39
Internal Capsule-Left	Mean Fibre Length	0.36	0.052	30
















Table 6. Correlations between mean plasma FT4 concentrations in the first 4 weeks after birth and Bayley’s III composite scores for neurodevelopmental outcome at 42 months


	N	R2	P value
Motor	48	0.25	0.084
Language	48	0.27	0.069
Cognition	48	0.35	0.016
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